SAFE Notes in Europe: Key Legal Differences from US SAFEs

Key Takeaways

• US SAFEs are often ill-suited or tax-inefficient in European jurisdictions without adaptation
• Each major European market has its own SAFE-equivalent instrument or commonly used functional equivalent
• Tax incentives (UK SEIS/EIS) require specific instrument structures
• German law prefers convertible loans with interest over pure SAFEs
• Cross-border rounds require careful structure to avoid mismatched conversion terms

Why US SAFEs Don't Work in Europe

The Y Combinator SAFE was designed for Delaware corporate law and US tax treatment—neither of which translates directly to European legal systems. Understanding why helps you choose the right instrument for your jurisdiction.

The US SAFE Model

Y Combinator introduced the SAFE (Simple Agreement for Future Equity) in 2013 as a founder-friendly alternative to convertible notes. Key features:

• Legal nature: Contractual right to future equity issuance (often described as warrant-like)
• Interest rate: None
• Maturity date: None
• Repayment obligation: None
• Conversion trigger: Next priced equity round or other specified equity financing/liquidity events
• Complexity: 1-5 pages, standardized

The simplicity is intentional—no negotiations over interest rates, no maturity pressure, no balance sheet liability. US investors and founders understand these terms implicitly.

Why It Breaks in Europe

Problem 1: Corporate Law Differences

US SAFEs rely on Delaware corporate law concepts that don't exist everywhere:

• Share classes: US SAFEs specify conversion to preferred shares with particular rights. European share class rules vary significantly by jurisdiction.
• Pre-emption rights: Many European jurisdictions have statutory pre-emption rights that must be disapplied for SAFE conversion—a process that varies by country.
• Form requirements: Germany, Austria, and other civil law jurisdictions have strict notarization or certification requirements that may apply depending on structure and entity type.

Problem 2: Tax Treatment Uncertainty

The US SAFE's tax treatment (neither debt nor equity until conversion) creates problems in Europe:

• UK: SAFEs don't qualify for SEIS/EIS tax relief until they convert—potentially years later. ASAs, structured differently, can qualify immediately if HMRC conditions are met.
• France: The PEA (Plan d'Épargne en Actions) tax wrapper has specific requirements that US-style SAFEs are unlikely to meet without careful structuring.
• Germany: Tax authorities may recharacterize the instrument, creating unexpected liability.

Problem 3: Investor Expectations

European investors, particularly angels and family offices, expect different protections:

• Interest accrual (even if nominal)
• Defined maturity or long-stop dates
• More explicit conversion mechanics
• Anti-dilution provisions

Presenting a pure US SAFE to European investors often generates confusion and negotiation friction.

European SAFE Equivalents by Country

Each major European market has developed its own instrument that achieves similar goals while respecting local legal and tax frameworks. Here's the landscape.

United Kingdom: ASA (Advance Subscription Agreement)

The UK's most common SAFE equivalent is the Advance Subscription Agreement (ASA), widely used alongside Convertible Loan Notes (CLNs).

Key Characteristics Comparison:

Why ASAs Work Better in the UK:

• Tax incentives: ASAs can qualify for SEIS (Seed Enterprise Investment Scheme) and EIS (Enterprise Investment Scheme), subject to HMRC conditions, including long-stop date and no repayment rights, offering investors 30-50% income tax relief. This is a massive investor incentive that US SAFEs cannot provide.
• Investor familiarity: UK angels expect ASA terms and understand the mechanics.
• Long-stop date: Unlike US SAFEs with no maturity, ASAs typically expect ≤6 months long-stop date for SEIS/EIS compliance.

Key UK Resources: SeedLegals SeedFAST (UK-adapted instrument), British Private Equity & Venture Capital Association templates

France: BSA-AIR

France has developed the BSA-AIR (Bon de Souscription d'Actions – Accord d'Investissement Rapide), a domesticated SAFE equivalent.

Key Characteristics:

BSA-AIR is a share warrant (BSA) with no interest, typically defined maturity (maturity/long-stop is common but not inherent), requires specific corporate formalities, may require AMF compliance (usually only relevant if public offering thresholds are crossed).

Why BSA-AIR Works in France:

• Legal recognition: French corporate law explicitly recognizes BSA (share warrants), providing clear legal framework.
• Tax optimization: Properly structured BSA-AIR can fit within French tax-advantaged investment schemes.
• Investor acceptance: French VCs and business angels are familiar with BSA structures.

French Considerations: AMF (Autorité des Marchés Financiers) rules may apply depending on offer structure. Social charges and employer contributions can affect conversion economics. Registration with the company register required.

Germany: Convertible Loan Agreements (CLAs)

Germany has been most resistant to pure SAFEs, with Convertible Loan Agreements (Wandeldarlehen) remaining the dominant instrument.

Key Characteristics:

German CLA is a loan (debt) with commonly includes interest, has maturity date, has repayment option often included, but can be waived/subordinated, strict form requirements (certification/notarization), appears as liability on balance sheet.

Why CLAs Dominate in Germany:

• Legal certainty: German corporate law clearly understands loans. The SAFE's hybrid nature creates uncertainty that German lawyers and investors dislike.
• Form requirements: German law requires certain corporate actions to be notarized or certified. The exact requirements for SAFE-like instruments are disputed, creating legal risk.
• Investor protection: German investors typically want the downside protection that debt status provides—if conversion never happens, they can be repaid.

German Considerations: Multilateral CLAs (one agreement with multiple investors) preferred over bilateral. Subordination clauses important to avoid insolvency complications. Recent court decisions have created uncertainty about signature certification requirements.

Other European Markets

• Netherlands: CLN or adapted SAFE (flexible, both used)
• Spain: Participative Loans (hybrid debt/equity structure)
• Italy: Convertible Bonds (strict corporate law requirements)
• Norway: SLIP similar to SAFE (adapted local version)
• Sweden: Qualified advance payment (SAFE adaptations emerging)
• Switzerland: Convertible Loans (outside EU, own framework)

Conversion Mechanics: Where Things Get Complicated

The moment a SAFE or equivalent converts to equity is where European complexity multiplies—pre-emption rights, share class rules, and registration requirements all come into play. Here's what to watch.

Pre-emption Rights

Most European jurisdictions have statutory pre-emption rights giving existing shareholders first right to new shares. US SAFEs assume these can be waived; in Europe:

• UK: Pre-emption waiver required via shareholder resolution (usually in articles)
• France: Shareholder assembly decision required
• Germany: Notarized shareholder resolution often required depending on capital increase structure
• Spain: General meeting resolution required

Risk: If pre-emption waiver isn't properly documented, conversion may be legally blocked or challenged by shareholders.

Share Class Creation

US SAFEs typically convert to preferred shares with specific rights. In Europe:

• UK: Share class creation requires articles amendment, shareholder resolution
• France: Creates new shares requiring specific corporate formalities
• Germany: Share classes less common; conversion often to ordinary shares with separate agreements for rights

Risk: Assuming US-style preferred share conversion will work identically creates legal friction and potential investor disputes.

Valuation Cap and Discount Interactions

The economic terms work similarly across jurisdictions, but mechanical differences matter:

• Valuation cap: Must align with local share valuation methods
• Discount: May interact with tax treatment differently
• MFN (Most Favored Nation): May trigger disclosure requirements

Risk: Using US templates without adapting economic term definitions can create conversion disputes.

Tax Implications by Jurisdiction

Tax treatment is often the deciding factor in instrument choice—UK SEIS/EIS alone can represent 30-50% of investor returns. Here's how taxation differs.

United Kingdom: SEIS/EIS Critical

Bottom Line: UK investors strongly prefer ASAs because they can claim tax relief immediately rather than waiting for conversion. A £100,000 SEIS investment with 50% relief effectively costs the investor £50,000—this is too significant to ignore.

France: PEA and Investor Taxation

Tax treatment depends heavily on exact structuring and investor profile. French investors may use PEA (Plan d'Épargne en Actions) accounts with favorable tax treatment: gains exempt from income tax after 5 years (social charges still apply). BSA-AIR can be structured for PEA eligibility; US-style SAFEs likely don't qualify. Additionally, French wealth tax (IFI) treatment may differ based on instrument classification.

Germany: Interest and Withholding

Tax treatment depends heavily on exact structuring and investor profile. German CLAs with interest create: interest income taxable to investor (capital gains tax ~26.4%), withholding tax obligations for the company, clear tax treatment but ongoing compliance burden. Pure SAFEs create uncertainty about whether capital gains or income treatment applies on conversion.

Cross-Border Investments

When investors from multiple jurisdictions participate: each investor's tax treatment follows their home jurisdiction, company must understand withholding obligations for each, instrument structure may need to accommodate multiple tax regimes.

Risk: A single instrument structure may not optimize for all investor jurisdictions.

Practical Guidance: Choosing the Right Instrument

The right instrument depends on your jurisdiction, investor base, and growth plans. Here's a decision framework.

When to choose each instrument:

• ASA/BSA-AIR: UK/France incorporation, SEIS/EIS investors, speed priority, uncertain timeline
• CLA/CLN: German incorporation, investor wants downside protection

UK-Incorporated Startups

• Default: ASA (SeedFAST or similar) if SEIS/EIS investors
• Alternative: CLN if investors prefer debt protection
• Avoid: Pure US SAFEs (tax inefficient for investors)

French-Incorporated Startups

• Default: BSA-AIR for local investors
• Alternative: SAFE adaptation if primarily non-French investors
• Consider: Legal review for AMF compliance

German-Incorporated Startups

• Default: Convertible Loan Agreement (Wandeldarlehen)
• Structure: Multilateral agreement, subordination clause, proper certification
• Avoid: Pure US SAFEs (legal uncertainty too high)

Cross-Border Structure

• Assess where the company is incorporated
• Consider where most investors are based
• Optimize primary instrument for largest investor group
• Document clear conversion mechanics for all parties

Common Mistakes and How to Avoid Them

European founders using US resources often make preventable errors. Here are the most common.

Mistake 1: Using Y Combinator Templates Directly

Problem: YC templates assume Delaware law and US tax treatment.

Solution: Use jurisdiction-specific templates:

• UK: SeedLegals, Seedrs, or lawyer-drafted ASAs
• France: BSA-AIR templates from French law firms
• Germany: Orrick, Noerr, or other German firm CLA templates

Mistake 2: Ignoring Tax Incentives

Problem: Structuring instruments that don't qualify for SEIS/EIS or equivalent.

Solution: Consult tax advisor before finalizing instrument structure. The 30-50% tax relief difference can make or break investor interest.

Mistake 3: Forgetting Form Requirements

Problem: German and other civil law jurisdictions have strict documentation requirements.

Solution: Work with local counsel to ensure proper certification/notarization, required registrations completed, corporate resolutions properly documented.

Mistake 4: Mismatched Conversion Terms

Problem: Investors from different jurisdictions expect different conversion mechanics.

Solution: Define "Qualified Financing" clearly and consistently, specify share class and rights at conversion, address pre-emption waiver explicitly.

Mistake 5: Underestimating Complexity

Problem: Assuming European SAFEs are as simple as US SAFEs.

Solution: Budget for local legal review (€2,000-5,000 per jurisdiction), tax advice on structure (€1,000-3,000), ongoing compliance costs.

Conclusion: Local Instruments, Same Goals

The goals of early-stage financing are the same everywhere: get capital into your company quickly without premature valuation discussions. The SAFE achieved this elegantly in the US market.

European founders can achieve the same goals, but they need to use instruments designed for their jurisdiction:

• UK: ASAs for SEIS/EIS eligibility
• France: BSA-AIR for local legal recognition
• Germany: CLAs for legal certainty and investor comfort

The economic outcomes are similar. The legal wrappers are different. Use the right instrument for your market, and you'll close rounds efficiently while keeping your investors happy and your cap table clean.

If you're raising from multiple European jurisdictions or planning cross-border growth, get local legal advice early. The €3,000-5,000 you spend on proper structuring will prevent far larger problems at your Series A when lawyers are examining your cap table and conversion history.

Reviewed by Outlex Legal Team

This content was reviewed by qualified legal professionals with experience advising European startups on compliance, contracts, and corporate matters. Outlex is backed by a major Portuguese law firm with expertise across EU jurisdictions.

Last updated: February 2026

Sources:

• Y Combinator SAFE Documentation
• SeedLegals UK Market Analysis
• Wolf Theiss - SAFEs as New Financing Instruments
• Orrick Legal Ninja - Convertible Loan Agreements in Germany
• BVCA Guidelines
• French Commercial Code - BSA Provisions

Disclaimer: This article provides general information about early-stage financing instruments. It does not constitute legal or tax advice. For advice specific to your situation, consult qualified legal and tax professionals in your jurisdiction.